Endonovo Therapeutics, Inc.
Income Statement
| Line Item | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5K | $45.2K | $87.5K | $121.5K | $11.0K | $650 | $2.3K | $316 |
| Cost of Revenue | $827 | — | $4.0K | $4.9K | $4.0K | $383 | $714 | $8.9K |
| Gross Profit | $693 | $45.2K | $83.5K | $116.6K | $6.9K | $267 | $1.6K | $-8.5K |
| Gross Margin | 45.6% | 100.0% | 95.4% | 96.0% | 63.3% | 41.1% | 68.7% | -2,704.1% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — |
| Operating Income | $-472.8K | $-1.1M | $-529.3K | $-483.1K | $-496.8K | $-1.8M | $-485.8K | $-373.8K |
| Operating Margin | -31,105.1% | -2,502.9% | -604.6% | -397.7% | -4,532.6% | -276,730.6% | -21,286.7% | -118,289.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-766.2K | $2.1M | $7.2M | $-12.9M | $-603.4K | $-2.5M | $-2.4M | $2.4M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-766.2K | $2.1M | $7.2M | $-12.9M | $-603.4K | $-2.5M | $-2.4M | $2.4M |
| Net Margin | -50,405.9% | 4,565.6% | 8,259.7% | -10,647.0% | -5,505.1% | -388,635.5% | -105,749.7% | 758,332.3% |
| EPS (Basic) | $0.00 | $0.00 | $0.03 | $-0.08 | $0.00 | $-0.01 | $-0.02 | $0.03 |
| EPS (Diluted) | $0.00 | $-0.01 | $0.00 | — | $0.00 | $-0.01 | $-0.02 | $0.03 |
| Shares Outstanding (Basic) | 298.4M | 276.3M | 251.4M | 139.2M | 307.2M | 268.7M | 158.0M | 119.7M |
| Shares Outstanding (Diluted) | 1.35B | 1.35B | 1.74B | 139.2M | 307.2M | 268.7M | 158.0M | 119.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |